N.C. jury levies $12.8M judgment in Novartis case; Study questions Plavix-aspirin combo;

@FiercePharma: J&J pulls more children's drugs off store shelves. News | Follow @FiercePharma

Special Report: FierceBiotech's Top Writers in Biotech. Report

> A North Carolina jury decided that Novartis failed to adequately warn about the risks of its Zometa and Aredia bone-strengthening meds and awarded $12.8 million to Rita Fussman, whose family claimed she suffered jawbone damage while dying of breast cancer last year. Article

> Plavix and aspirin are often prescribed together to prevent blood clots because warfarin can lead to uncontrolled bleeding in some patients, but a new study has found the combination treatment can also cause serious hemorrhages. Story

> Acrux, the developer of an underarm testosterone lotion with Eli Lilly, rose to a record in Australian trading after the treatment was approved for sale in the U.S. Report

Special Report: The 2010 Biotech Graveyard: Report

> German executives of drugmaker Bayer must fly to America for depositions in litigation over its contraceptive drugs Yaz, Yasmin and Ocella, U.S. District Judge David Herndon has decided. News

> Sinopharm Group said it planned to issue up to 5 billion yuan ($752.7 million) worth of medium term notes, raising capital to fund operational activities, adding liquidity and for repaying bank loans. Report

> Wockhardt has restarted talks with Abbott Laboratories to sell its nutrition business, Bloomberg UTV reported, citing sources; the company is seeking as much as 9 billion rupees for the unit, the report said. Item

> A drug used to euthanize animals has been approved for use in capital punishment in Oklahoma, a decision that could affect other states scrambling to address a nationwide shortage of a key anesthetic used in executions. Story

> Gilead Sciences asked the FDA to approve a single pill combination of its HIV treatment Truvada and Tibotec Pharmaceuticals' rilpivirine. Article

> Roche is selling its Roche Carolina plant in Florence, South Carolina, which has 330 workers, as part of a move to cut its employment by 4,800 worldwide. News

Biotech News

 @FierceBiotech: Uphill climb gets even steeper for biotech IPOs. Report | Follow @FierceBiotech

 @JohnCFierce: A few weeks ago Amira's Bob Baltera was brimming with confidence about new financing. Today, not so much. Story | Follow @JohnCFierce

> Twin blows spur a crisis of confidence in RNAi. Item 

> Roche dumps hep C development deal with Ligand. Article 

> China Medicine taps new CFO. Item

Drug Delivery News

> Nanoparticle sticks around to make sure cancer cells are dead. News

> Carbon nanotubes, electrical fields double-team tumors. Item

> 'Nanobioconjugate' hits brain tumor target. Story

> Nose-to-brain delivery has a rat problem. Article

> Hedge fund Ramius tries to shake up SurModics. Report

> Graphene works in drug delivery, but will it leave the body? Item

Medical Device News

> Mela wins narrow backing for skin cancer detector. Story

> Boston Sci ($BSX) agrees to pay up to $450M for Sadra Medical. Article 

> L.H., Merit plan med device hirings. Report 

> Medtronic ($MDT) inks deal to acquire Ardian for $800M. Story 

> AstraZeneca ($AZN) plots $2B sale of device unit. News 

> Medtronic ($MDT) lowers earnings expectations again. Item

And Finally... Combining aerobic exercise and resistance training lowered blood-sugar levels in people with Type 2 diabetes, a new study has found. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.